Castle Biosciences (CSTL) Total Liabilities (2018 - 2026)

Castle Biosciences has disclosed Total Liabilities across 9 years of filings, most recently posting $86.4 million for Q1 2026.

• Total Liabilities for Q1 2026 came in at $86.4 million, up 40.68% year-over-year; the trailing twelve-month figure through Mar 2026 was $86.4 million (up 40.68% YoY), and the FY2025 annual result was $107.7 million, up 42.82% from the prior year.
• Total Liabilities came in at $86.4 million for Q1 2026 at Castle Biosciences, down from $107.7 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $107.7 million in Q4 2025 to a low of $36.7 million in Q2 2022.
• The 5-year median for Total Liabilities is $61.4 million (2025), against an average of $64.0 million.
• Across the five-year window, Total Liabilities soared 151.21% in 2022 and retreated 11.36% in 2023, its largest moves.
• Castle Biosciences' Total Liabilities stood at $48.2 million in 2022, then increased by 28.83% to $62.1 million in 2023, then increased by 21.47% to $75.4 million in 2024, then soared by 42.82% to $107.7 million in 2025, then dropped by 19.77% to $86.4 million in 2026.
• The last three Total Liabilities figures came in at $86.4 million (Q1 2026), $107.7 million (Q4 2025), and $95.7 million (Q3 2025), per Business Quant data.